Schapira on Breast Cancer and Survivorship

 
 

  • Isolation and Burnout in Physician Culture: Innovative Solutions For almost 20 years, Dr Tait Shanafelt has studied the causes and effects of physician burnout. In this interview, he provides his insight on this serious issue.
  • Clinical Takeaways From the 2018 Cancer Survivorship Symposium Cancer Survivorship expert Lidia Schapira reflects on the most important topics presented at the 2018 Cancer Survivorship Symposium.
  • Intermittent Versus Continuous Extended Adjuvant Letrozole A new study supports the approach of 'pausing' letrozole treatment for patients whose previous adjuvant therapy included an aromatase inhibitor, argues Lidia Schapira.
  • Overprescribing Opioids After Surgery for Cancer Oncologists need to counsel patients more actively about postoperative pain and work collaboratively in multidisciplinary teams to avoid overprescribing opioids, argues Dr Lidia Schapira.
  • New Potential Drug Therapy for AI-Associated Arthralgia The anti-depressant duloxetine effectively reduced musculoskeletal symptoms early in the course of treatment with aromatase inhibitors for early-stage breast cancer.
  • 'Right' Endocrine Therapy a Question in Youngest BC Patients An analysis of the SOFT and TEXT trial results throws some light on the question of which endocrine therapy is best in young patients with breast cancer.
  • Breast Reconstruction Methods Not Considered Equal Dr Lidia Schapira discusses the first randomized trial that looks at women's reported quality of life after two methods of breast reconstruction: implant and autologous tissue reconstruction.
  • Breast Cancer Survivorship: Can We Get It Right? Providing essential care for 3 million US breast cancer survivors is challenging, prompting Dr Lidia Schapira to summarize new data on symptom management, risk assessment, and questionable therapies.
  • FALCON Breast Cancer Trial: Who's Naive Here? In the FALCON trial, fulvestrant improved PFS in ER+ metastatic breast cancer patients who were endocrine-therapy naive, but the trial failed to answer key clinical questions, says Dr Lidia Schapira.
  • Ribociclib Increases Survival in HR+ Advanced Breast Cancer, But… Ribociclib + letrozole improves PFS in HR+ breast cancer, but Dr Lidia Schapira says more data are needed to identify which patients should receive endocrine therapy alone or combination therapy.
  • The Cancer Survivor in Primary Care   Dr Lidia Schapira stresses the importance of a team approach for the cancer survivor that includes the primary care clinician.
  • How Helpful Is Oncotype DX in Breast Cancer? Dr Lidia Schapira reports on the TAILORx results, in which Oncotype DX identified women at low risk for recurrence, but she says the data cannot be extrapolated to patients at higher risk.
  • Individualized Cancer Survivorship Dr Kevin Oeffinger, cochair of the 2016 Cancer Survivorship Symposium, outlines an approach to cancer survivorship that tailors care the individual across the oncology/primary care spectrum.
  • Tamoxifen or AI: Breast Cancer Subtypes Narrow Choice In early breast cancer, the biologic subtype provides a clue to the optimal choice of adjuvant endocrine therapy, as indicated by data from BIG 1-98 and discussed by Dr Lidia Schapira.
  • Sex After Cancer: The Unaddressed Issue Sex is not a regular topic between oncologist and patient. But Dr Don Dizon says it should be, given that a large majority of cancer patients and survivors have issues of sexual function.